Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: The pharmaceutical industry is applying Active Learning in various areas which includes the integration of experiment and computational modeling, automation, big data analytics, and informatics. This session will focus on pharma preparations and applications of AI and Machine Learning across drug discovery and development – various examples will demonstrate how pharma is harnessing the opportunity of large data sets to predict and improve human translation in clinical studies.
Session Chair Profile
Ph.D., Co-Lead and Chief Operating Officer, GSK; COO, ATOM Consortium
Biography
Stacie Calad-Thomson is Chief Operating Officer of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a new public-private partnership that aims to accelerate the discovery of effective cancer therapies through integration of high-performance computing, diverse biological data, and emerging biotechnologies. Founding consortium members include the Department of Energy’s Lawrence Livermore National Laboratory, GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. The goal of the consortium is to create a new paradigm of drug discovery that would reduce the time from an identified drug target to clinical candidate from the current approximately six years to just 12 months. Stacie has worked for GSK, starting as a chemist and moving into business strategy and operations roles within R&D Platform Technology & Sciences, where she led several change initiatives. She has a BS (UC Berkeley) and a PhD (UC Irvine) in chemistry.
Speaker Profile
Ph.D., Head of Artificial Intelligence, Genentech
Biography
Kim has been involved in large scale machine learning and medical informatics initiatives for over 15 years, over a range of ventures from computational drug design to disease risk prediction. He is currently the Head of the Artificial Intelligence group for Genentech, Early Clinical Development. Recently, he served as founder and Chief Data Scientist at Lumiata, a predictive health analytics company. Kim received degrees from the University of Adelaide (Science and Medicine), and a PhD from the University of Melbourne (Australia) He was a Peter Doherty fellow and received postdoctoral training at the University of Cambridge, and Stanford University (Dr Vijay Pande). He then held leadership and consulting roles in the pharmaceutical and medical informatics industry. Kim began his industry career at Vertex Pharmaceuticals (Pat Walters) Following this, Kim worked as the founding team for Discovery Engine (acquired by Twitter in 2009) and health informatics at Gliimpse (acquired by Apple in 2017). Kim currently serves on the board of OpenEye Scientific Inc.
Speaker Profile
M.D., Ph.D., Senior Director-Neuroscience Tailoring, Eli Lilly and Company
Biography
Bradley Miller manages the Neuroscience Tailored Therapeutics group at Eli Lilly and Company. In this position, he formulates strategy and oversees execution of biomarker initiatives ranging from discovery to late phase clinical trials. The evaluation, use and analysis of digital tools and applications in clinical development is an increasingly prominent activity in his group. Prior to this position, he was an Associate Medical Advisor in Translational Therapeutics at Eli Lilly and Company where he worked with Lilly scientists, physicians and others to define and interpret biomarkers and assays for agents produced by Lilly to incorporate them into clinical trials. Before his career at Eli Lilly and Company, Dr. Miller was an academic physician scientist with appointments at the University of Virginia and Texas Tech University. In these roles, he provided service in medicine (neuropathology, general surgical pathology and clinical chemistry) and research (neurology, tissue banking and biochemistry).
Speaker Profile
M.D., Ph.D., VP Scientific & Medical Affairs, Molecular Health GmbH
Biography
Dr Armin Schneider has 20 years track record in leading roles in Biotech drug discovery and development and MD PhD from the University of Heidelberg, Germany. At Molecular Health, Armin pioneers the utilization of the company’s technology, Dataome® – a mighty clinical-molecular knowledge base of drugs, diseases and outcomes into machine learning applications and predictive algorithms to predict drug outcomes and R&D efficiency. He has authored over 150 publications and owns numerous patent families and has a strong background in neurology, pharmacology, molecular biology, and statistics, and specific interest in questions of applying advanced statistical methodology to drug development.
